Astria Therapeutics (ATXS) Income from Continuing Operations: 2017-2018
Historic Income from Continuing Operations for Astria Therapeutics (ATXS) over the last 2 years, with Dec 2018 value amounting to -$5.9 million.
- Astria Therapeutics' Income from Continuing Operations fell 6.65% to -$5.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$26.0 million, marking a year-over-year increase of 5.05%. This contributed to the annual value of -$26.0 million for FY2018, which is 4.93% up from last year.
- According to the latest figures from Q4 2018, Astria Therapeutics' Income from Continuing Operations is -$5.9 million, which was down 1.27% from -$5.8 million recorded in Q3 2018.
- Astria Therapeutics' 5-year Income from Continuing Operations high stood at -$5.5 million for Q4 2017, and its period low was -$7.9 million during Q1 2017.
- Its 2-year average for Income from Continuing Operations is -$6.7 million, with a median of -$6.8 million in 2017.
- The largest annual percentage gain for Astria Therapeutics' Income from Continuing Operations in the last 5 years was 16.70% (2018), contrasted with its biggest fall of 6.65% (2018).
- Astria Therapeutics' Income from Continuing Operations (Quarterly) stood at -$5.5 million in 2017, then dropped by 6.65% to -$5.9 million in 2018.
- Its last three reported values are -$5.9 million in Q4 2018, -$5.8 million for Q3 2018, and -$6.6 million during Q2 2018.